Randomized phase-3 study: tarlatamab, a DLL3-targeting bispecific t-cell engager (BiTE), compared to standard-of-care in relapsed small cell lung cancer (DeLLphi-304)
Rodriguez, L. P. A. Felip, E. Ahn, M. J. Blackhall, Fiona H Borghaei, H. Cho, B. C. Johnson, M. L. Ramalingam, S. S. Reck, M. Jiang, T.
Rodriguez, L. P. A.
Felip, E.
Ahn, M. J.
Blackhall, Fiona H
Borghaei, H.
Cho, B. C.
Johnson, M. L.
Ramalingam, S. S.
Reck, M.
Jiang, T.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Citation
Rodriguez LPA, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, et al. Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304). JOURNAL OF THORACIC ONCOLOGY. 2024 JUL;19(7):E34-E. PubMed PMID: WOS:001277064200073. English.